Abstract Number: 1402 • ACR Convergence 2020
Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Background/Purpose: Orchestration of immune checkpoints is central for the outcome of immune activation, especially in patients with rheumatoid arthritis (RA). We have previously shown that…Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…Abstract Number: 1558 • ACR Convergence 2020
Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
Background/Purpose: Preclinical studies show that tsDMARDs such as baricitinib may be a therapeutic agent for bone anabolic effects by increasing osteoblast function in inflammatory conditions.[1]…Abstract Number: 1713 • ACR Convergence 2020
Exploring Novel Tenosynovitis and Combined Inflammation Imaging Outcomes: Results from a Randomized Controlled Trial in Early Rheumatoid Arthritis
Background/Purpose: MRI trial outcomes have largely focused on synovitis, bone marrow edema (BME), and erosions. Tenosynovitis is a common manifestation of RA, but is relatively…Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…Abstract Number: 1763 • ACR Convergence 2020
Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus…Abstract Number: 1976 • ACR Convergence 2020
High Disease Activity Is Associated with Incident Osteoporotic Fractures Among Veterans with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for osteoporosis and fractures yet the disease specific contributions to osteoporotic fractures (OFX) are not well understood.…Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…Abstract Number: 0031 • ACR Convergence 2020
Metabolomics Profiling Predicts Outcome of Tocilizumab in Rheumatoid Arthritis
Background/Purpose: Metabolomics may provide information about the activity and severity of specific diseases and potentially help discriminate between diseases. Choosing the right biological therapy earlier…Abstract Number: 0103 • ACR Convergence 2020
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…Abstract Number: 0148 • ACR Convergence 2020
Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study
Background/Purpose: Physicians often consider adverse events when choosing therapies for PsA and RA but may give less attention to other ways in which treatments affect…Abstract Number: 0185 • ACR Convergence 2020
Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease
Background/Purpose: The aim of our study was to assess the prevalence of migraine and neuropathic pain in a sample of patients with chronic inflammatory rheumatism…Abstract Number: 0201 • ACR Convergence 2020
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)
Background/Purpose: Proinflammatory cytokine activation of JAK/STAT signal pathway is critical in the pathogenesis and progression of RA. SHR0302, a potent and selective inhibitor of JAK1,…Abstract Number: 0217 • ACR Convergence 2020
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results
Background/Purpose: Filgotinib (FIL) is an oral, potent, selective JAK 1 inhibitor. FINCH 3 assessed FIL efficacy and safety in methotrexate (MTX)-naïve patients (pts) with rheumatoid…
- « Previous Page
- 1
- …
- 151
- 152
- 153
- 154
- 155
- …
- 188
- Next Page »